| Abstract Title | Authors | Session # | Session Day & Time |
| Methodology To Objectively Prioritize Therapeutic Hypotheses in Alzheimer’s Disease Via Target Risk Scoring and Biological Domain Annotation | S.Keegan, J. Wiley, G. Cary, J. Gockley, J. Liu, L. Heath, A. Greenwood, L. Mangravite, B. Logsdon, R. Butler, J. Zhang, H. Wu, K. Huang, F. Longo, A. Levey, G.W. Carter | 085.11 | 11/12/2022, 1-5 PM |
| Agora: An open platform for exploration of Alzheimer’s Disease evidence | J.S. Britton, J. Glockley, L. Bradic, M.S. Fazza, M. Courville, J. Hendrickson, K. Do, N. Grosenbacher, S. Simon, D.S. Aluthgamage, C.E. Alvarado, J. Hodgson, A.K. Greenwood | 119.28 | 11/13/2022, 8 AM-12 PM |
| The MODEL-AD Explorer: An interactive, open access dashboard sharing phenotypic and gene expression data from Alzheimer’s mouse models | J.M. Hendrickson, S. Gelfand, R. Pandey, R. Yaxley, III, A. Gomez-Arboledas, G. Milinkeviciute, J.S. Britton, N. Rezaie, A. Uyar, A.L. Oblak, J. Mincer, M.A. Peters, A. Vander Linden, J. Schneider, M.S. Fazza, A. Mortazavi, F.M. Laferla, A.J. Tenner, B.T. Lamb, K. Green, G.W. Carter, A.K. Greenwood | 119.29 | 11/13/2022, 8 AM–12PM |
| Inpp5d deficiency attenuates amyloid pathology in a mouse model of Alzheimer’s Disease | P.B.-C. Lin, A.P.-Y. Tsai, D. Soni, A. Lee-Gosselin, M. Moutinho, S. Puntambekar, G.E. Landreth, B.T. Lamb, A. Oblak | 195.15 | 11/13/2022, 1-5 PM |
| Plcg2 variants elicit differential microglial responses and disease pathology in Alzheimer’s Disease | S.J. Bissel, A.P. Tsai, P.B.-C. Lin, C. Dong, E. Messenger, M. Moutinho, G. Xu, Y. Liu, A. Oblak, K. Nho, B.T. Lamb, G.E. Landreth | 275.02 | 11/14/2022, 8 AM-12 PM |
| Ozone dysregulates astrocyte-associated proteins in the amyloid plaque microenvironment | C. Ahmed, H.J. Greve, C. Garza-Lombo, J.A. Johnson, Jr., A. Oblak, M. Block | 276.04 | 11/14/2022, 8 AM-12 PM |
| The role of INPP5D in tau pathology | D. Soni, P.B.-C. Lin, A. Lee-Gosselin, E. Mason, A.P.-Y. Tsai, M. Moutinho, B.T. Lamb, S. Chu, A. Oblak | 276.07 | 11/14/2022, 8 AM-12 PM |
| Characterization of aging X genetic X environment as precision disease models for evaluation of therapeutic interventions for the treatment of late-onset Alzheimer’s disease | M. Sasner, A. Oblak, K.P. Kotredes, D. Garceau, S.-P. G. Williams, S. Doolen, K.A. Haynes, G. Little, D.S. Santos, C. Ingraham, C. Lloyd, B. Perkins, P.R. Territo, B.T. Lamb, G.W. Carter, G. Howell, S.J. Sukoff Rizzo | 370.12 | 11/14/2022, 1-5 PM |
| Human microRNA-298 (miR-298) in biochemical cascades leading to Alzheimer’s Disease (AD) | R. Wang, N. Chopra, B. Maloney, B.T. Lamb, A.J. Saykin, K. Sambamurti, S.E. Counts, D.K. Lahiri | 426.06 | 11/15/2022, 9:15-9:30 AM |
| Reduced PLCG2 expression alters microglial responses and exacerbates disease pathology in a murine model of Alzheimer’s Disease | E. Messenger, A.P. Tsai, C. Dong, P.B.-C. Lin, A. Oblak, M. Moutinho, G. Xu, Y. Liu, K. Nho, S.J. Bissel, B.T. Lamb, G.E. Landreth | 529.17 | 11/15/2022, 1-5 PM |
| Inpp5d modulates tau pathology in vivo | A.L. Oblak, A. Lee-Gosselin, D. Soni, B.T. Lamb, C.A. Lasgna-Reeves | 535.17 | 11/15/2022, 1-5 PM |
| Transcriptional assessment of novel mouse models harboring human genetic variants associated with late-onset Alzheimer’s disease | G. Carter, C. Preuss, R. Pandey, A. Uyar, D. Garceau, K. P. Kotredes, H. Williams, A. Oblak, P. B.-C. Lin, B. Perkins, D. Soni, C. Ingraham, A. Lee-Gosselin, B.T. Lamb, G.R. Howell, M. Sasner | 613.20 | 11/16/2022, 8 AM-12 PM |
| Genetically diverse mouse models of alzheimer’s Disease reveal an association between glycan metabolism and cerebral amyloid angiopathy | K.J. Elk, A. Uyar, D. Garceau, R. O’Rourke, K.P. Kotredes, K.D. Onos, G.W. Carter, G.R. Howell, M. Sasner | 613.21 | 11/16/2022, 8 AM-12 PM |
| Assessing the role of ABCA7*A1527G risk in a novel mouse model late-onset Alzheimer’s disease | P.R. Territo, A. Oblak, E. Chumin, S. Persohn, A. Bedwell, K. Eldridge, R. Speedy, K.P. Kotredes, R. Pandey, S.J. Sukoff Rizzo4, G.W. Carter, B.T. Lamb, M. Sasner, G.R. Howell | 616.08 | 11/16/2022, 8 AM-12 PM |
| Targeting the immune contributioins to neurodegeneration via the IL1RAP signaling axis | K.P. Kotredes, G.A. Prieto, M. Sasner, G.W. Carter, C.W. Cotman, G.R. Howell | 624.13 | 11/16/2022, 8 AM-12 PM |
